Find clinical trials for Chronic Lymphocytic Leukemia in Montréal, QC
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Chronic Lymphocytic Leukemia trials near Montréal, QC, CAN:
objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic...
Phase 3
Montreal, Quebec, Canada and 230 other locations
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic...
Phase 3
Montréal, Quebec, Canada and 149 other locations
of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic...
Phase 3
Greenfield Park, Quebec, Canada and 49 other locations
The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzum...
Phase 3
Montreal, Quebec, Canada and 86 other locations
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...
Phase 3
Montreal, Quebec, Canada and 216 other locations
This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in partici...
Phase 1, Phase 2
Montréal, Quebec, Canada and 48 other locations
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination wit...
Phase 3
Montreal, Quebec, Canada and 170 other locations
venetoclax versus obinutuzumab + chlorambucil in participants with chronic lymphocytic leukemia (CLL) and coexisting medic...
Phase 3
Montreal, Quebec, Canada and 136 other locations
the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic...
Phase 3
Montreal, Canada and 156 other locations
This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with sel...
Phase 1
Montreal, Quebec, Canada and 23 other locations
Clinical trials
Research sites
Resources
Legal